Molindone (Molindone Hydrochloride)

An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to moderate affinity for cholinergic and alpha-adrenergic receptors. Some electrophysiologic data from animals indicate that molindone has certain characteristics that resemble those of CLOZAPINE. (From AMA Drug Evaluations Annual, 1994, p283)

Also Known As:

Molindone Hydrochloride; Moban; Molindone Monohydrochloride; Hydrochloride, Molindone; Monohydrochloride, Molindone; 4H-Indol-4-one, 3-ethyl-1,5,6,7-tetrahydro-2-methyl-5-(4-morpholinylmethyl)-

Networked: 78 relevant articles (8 outcomes, 12 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Molindone: 78

Experts

1.	Findling, Robert L: 7 articles (01/2021 - 08/2007)
2.	Frazier, Jean A: 4 articles (05/2012 - 08/2007)
3.	Hamer, Robert M: 4 articles (05/2012 - 08/2007)
4.	Lieberman, Jeffrey A: 4 articles (05/2012 - 08/2007)
5.	Sikich, Linmarie: 4 articles (05/2012 - 08/2007)
6.	Vitiello, Benedetto: 4 articles (05/2012 - 08/2007)
7.	Bloch, Michael H: 3 articles (01/2021 - 01/2017)
8.	Taylor, Jerome H: 3 articles (01/2021 - 01/2017)
9.	Yu, Chungping: 3 articles (03/2019 - 01/2018)
10.	McClellan, Jon: 3 articles (05/2012 - 11/2008)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 06/01/2008 - "Efficacy of molindone in treatment-refractory agitated schizophrenia: three case reports." 10/01/1985 - "An adolescent male with chronic schizophrenic disorder, paranoid type, was treated with molindone. " 05/01/1973 - "Treatment of acute schizophrenia with molindone." 09/01/1970 - "Molindone in chronic schizophrenia." 01/24/2007 - "We included all randomised controlled trials that compared molindone to other treatments for schizophrenia and schizophrenia-like psychoses. "
2.	Psychotic Disorders (Schizoaffective Disorder) 01/24/2007 - "We included all randomised controlled trials that compared molindone to other treatments for schizophrenia and schizophrenia-like psychoses. " 01/01/2000 - "All randomised controlled trials that compared molindone to other treatments for schizophrenia and schizophrenia-like psychoses were included by independent assessment. " 01/01/1993 - "Four patients with HIV infection and psychosis from various etiologies, refractory to standard treatments, and suffering from severe extrapyramidal symptoms (EPS), had a marked beneficial response to molindone. " 01/24/2007 - "To determine the effects of molindone compared with placebo, typical and other atypical antipsychotic drugs for schizophrenia and related psychoses. " 01/01/2000 - "To determine the effects of molindone compared with placebo, typical and other atypical antipsychotic drugs for schizophrenia and related psychoses. "
3.	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 03/01/2019 - "SPN-810 (extended-release molindone) is currently being investigated as a novel treatment for children with IA and ADHD. " 01/01/2021 - "Objective: To evaluate efficacy and safety of SPN-810 (extended-release molindone) in a Phase-2b, randomized, double-blind, placebo-controlled, dose-ranging study of children (6-12 years) with ADHD and persistent impulsive aggression (IA). " 01/01/2021 - "A Double-Blind, Randomized Study of Extended-Release Molindone for Impulsive Aggression in ADHD." 04/01/2012 - "A phase 2a randomized, parallel group, dose-ranging study of molindone in children with attention-deficit/hyperactivity disorder and persistent, serious conduct problems." 01/01/2018 - "SPN-810 (extended-release molindone) is being developed for the novel indication of IA and is currently being studied in patients treated for ADHD. "
4.	Neuroleptic Malignant Syndrome 10/01/1991 - "Neuroleptic malignant syndrome possibly caused by molindone hydrochloride." 09/01/1989 - "Reinstitution of neuroleptic treatment with molindone in a patient with a history of neuroleptic malignant syndrome." 09/01/1989 - "A case is reported in which neuroleptic treatment was successfully reintroduced with molindone after previous bouts of neuroleptic malignant syndrome (NMS) with trifluoperazine and thioridazine. " 01/01/1989 - "In this case, a patient with a history of probable neuroleptic malignant syndrome caused by administration, as single agents, of haloperidol, molindone, and lithium was later treated successfully with the novel antipsychotic clozapine. "
5.	Treatment-Resistant Depressive Disorder 08/01/1981 - "These results suggest that molindone in low dosage may be helpful in the management of refractory depression and may have the further advantage of producing a more rapid response to treatment with fewer disabling side effects." 08/01/1981 - "Comparison of molindone and tranylcypromine in the treatment of refractory depression."

Related Drugs and Biologics

1.	Antipsychotic Agents (Antipsychotics)
2.	Risperidone (Risperdal Consta)
3.	Olanzapine (Zyprexa)
4.	Dopamine (Intropin)
5.	Haloperidol (Haldol)
6.	Clozapine (Clozaril)
7.	Lithium
8.	Serotonin Antagonists
9.	Dopamine Antagonists
10.	Dopamine Receptors (Dopamine Receptor)

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)